|
| | | | | | | | | | | |
| Name | Indication | Class | Rights | Approved | Admin | IP | | Price | 47.73 | |
| Comirnaty | COVID-19 | mRNA vaccine | BNTX | | SC | MRNA dispute | | Shares | 5718 | Q322 |
| Ibrance (palbociclib) | Breast Cancer | CDK4/6 | 1 | | Oral | | | MC | 272920.13999999996 | |
| Prevnar | Pneumococcal Vaccine | Vaccine | WYE | 2/17/2000 | IM | Vaccine | | Cash | 50011 | Q322 |
| Prevnar 13 | Pneumococcal Vaccine | Vaccine | 1 | 2/24/2010 | IM | Vaccine | | Debt | 36669 | Q322 |
| Paxlovid (nirmatrelvir) | COVID-19 | Antiviral | 1 | | Oral | | | EV | 259578.13999999996 | |
| Vyndaqel (tafamidis meglumine) | Transthyretin Cardiomyopathy, FAP | TTR Inhibitor | 1 | | Oral | | | | | |
| Eliquis (apixaban) | DVT, PE, Afib | Factor Xa | BMY | 12/28/2012 | Oral | | | CEO: Albert Bourla | | |
| Enbrel (etanercept) | Rheumatoid Arthritis | Anti-TNF | AMGN | 11/2/1998 | SC | | | CFO: David Denton replaced Frank D'Amelio, who retired. | | |
| Xeljanz (tofacitinib) | Rheumatoid Arthritis | JAK3 | 1 | 11/6/2012 | Oral | | | Supply Chain: Mike McDermott | | |
| Inlyta (axitinib) | NSCLC, Thyroid, BC | VEGF | 1 | 1/27/2012 | Oral | | | | | |
| Xalkori (crizotinib) | NSCLC | ALK | 1 | 8/26/2011 | Oral | 2025, 2029 NCE | | | | |
| Sutent (sunitinib) | GIST, RCC | TK | 1 | 1/26/2006 | Oral | LOE | | | | |
| Geotropin (somatropin) | Growth Deficiency | rDNA | 1 | 1/27/1998 | SC? | Biologic | | | | |
| BeneFIX (nonacog alfa) | Hemophilia | Factor IX | 1 | 2/11/1997 | IV | Biologic | | | | |
| Xyntha/Refacto | Hemophilia | Factor VIII | DYAX? | | IV | Biologic | | | | |
| Zyvox (linezolid) | Anti-infective | Oxazolidinone | 1 | 4/18/2000 | All | | | | | |
| Chantix (varenicline) | Smoking Cessation | Nicotinic | 1 | 5/10/2006 | Oral | 5/10/2020, 8/19/2022, p4 filed 7/2010 | | | | |
| Vfend (voriconazole) | Infections | Antifungal | 1 | 5/4/2002 | All | | | | | |
| Toviaz (fesoterodine) | OAB | Muscarinic | UCB | 2008 | Oral | | | | | |
| Besponsa (inotuzumab ozogamicin) | ALL | CD22 ADC | 1 | | | | | | | |
| Myfembree (relugolix, estradiol, norethindrone) | Endometriosis, UF | GNRH? | MYOV | | Oral | | | | | |
| Trazimera (PF-05280014) | Breast Cancer | HER2 | 1 | | IV | | | | | |
| TicoVac | TBE | Vaccine | 1 | | | | | | | |
| Nurtec/Vydura (rimegepant) | Migraine | CGRP | 1 | 4/2022 EC | Oral | | | | | |
| Ngenla (somatrogon) | Growth Deficiency | rHGH | OPK | | qw SC | | | | | |
| Lorbrena/Lorviqua (lorlatinib) | Cancer | ALK | 1 | | Oral | | | | | |
| Trumenba (PF-05212366/MnB rLP2086) | Meningitis | Vaccine | 1 | | | | | Biohaven: 11.6B | | |
| Daurismo (glasdegib), PF-04449913 | AML | Hedgehog | 1 | | | | | Arena: 6.2B completed 3/11/22 | | |
| Zirabev (PF-06439535) | Cancer | Biosimilar Avastin | 1 | | | | | Trillium: 2.0B completed 11/17/21 | | |
| Premarin (estrogen) | Hot Flashes | HRT | 1 | 1984 | Oral | Biologic | | ReViral | | |
| Talzenna (talazoparib) | CRPC | PARP | 1 | | | | | | | |
| Cibinqo (abrocitinib) fka PF-04965842 | | | 1 | 1/14/2002 | Oral | | | | | |
| Pristiq (desvenlafaxine) | Depression | SNRI | 1 | 2/29/2008 | Oral | | | Amplyx | | |
| | | | | Phase | | | | Haleon (HLN) - 32% ownership | | |
| | COVID-19 | bivalent mRNA vaccine | BNTX | | | | | Priovant (brepocitinib, ropsacitinib) | | |
| | COVID-19 | enhanced mRNA vaccine | BNTX | | | | | | | |
| | Influenza | modRNA vaccine | BNTX? | | | | | | | |
| danuglipron (PF-06882961) | Type 2 Diabetes | GLP-1 | 1 | | Oral | | | International FY ends 11/30 | | |
| | | anti-IFN-beta | 1 | | | | | | | |
| sasanlimab (PF-06801591) | nmiBC | PD-1 mab (subcut) | 100%? | | | | | | | |
| Abrilada (adalimumab, PF-06410293) | Rheumatoid Arthritis | TNFalpha | 1 | Q422 PDUFA | SC | | | Meridian divested ($300m annual revenue) 12/31/21 | | |
| etrasimod | Ulcerative Colitis, AA, Crohn's, AD, EE | S1P | 100%? | Filing | Oral | | | Durham, NC gene therapy plant | | |
| elranatamab | Multiple Myeloma | BCMA/CD3 | 100%? | II - Launch 2023 | | | | | | |
| TTI-622 | DLBCL | CD47/SIRPalpha | 100%? | | | | | | | |
| fordadistrogene movaparvovec | DMD | AAV | 1 | III | | | | | | |
| giroctocogene fitelparvovec | Hemophilia A | AAV | SGMO | III | | | | | | |
| fidanacogene elaparvovec | Hemophilia B | | | | | | | | | |
| ervogastat (PF-06865571) | NASH | DGAT2 | 1 | II | | | | | | |
| clesacostat (PF-05221304) | NASH | acetyl-CoA carboxylase | 1 | II | | | | | | |
| ARV-471 | Breast Cancer | ER PROTAC | ARVN | II | | | | | | |
| ritlectinib (PF-06651600) | Alopecia, Vitiligo, UC, Crohn's | JAK | | Filed? Launch 2023? | | | | | | |
| PF-06928316 | RSV (older adults) | Vaccine | 1 | II | | | | | | |
| VLA15 | Lyme vaccine | Vaccine | VALN | II | | | | | | |
| PF-06425090 | C. Difficile | Vaccine | 1 | III | | | | | | |
| sisunatovir | RSV | Fusion inhibitor | 100% (ReViral) | II | | | | | | |
| GBT-601 | Sickle Cell | | | I | | | | | | |
| PF-07220060 | Breast Cancer | CDK4i | | | | | | | | |
| | Liver, Muscle, CNS RD | Base Editor | BEAM | PC | | | | | | |
| | Shingles | Vaccine | BNTX | PC | | | | | | |
| PF-05280586 | Rheumatoid Arthritis | Biosimilar Rituxan | 1 | I | | | | | | |
| | | | | | | | | | | |
| | | | | January 2007: Fesoterodine PDUFA - approvable | | | | | | |
| | | | | June 2007: Resubmitted dalbavancin filing. | | | | | | |
| | | | | 10/28/2008: ACR - CP-690,550 28-week data. | | | | | | |
| | | | | January 2009: CRL for Fablyn. | | | | | | |
| | | | | Early 2009: Launch fesoterodine. | | | | | | |
| | | | | 2010: Acquires KG. | | | | | | |
| | | | | 2/1/11: Reports quarter, plan to cut R&D, exit UK site, buyback upped to $9bn. | | | | | | |
| | | | | 2/2/11: Ex-dividend. | | | | | | |
| | | | | 2/2011: Pfizer acquires Ferrosan consumer health. | | | | | | |
| | | | | 3/2011: Pfizer completes King acquisition. | | | | | | |
| | | | | 8/2011: Capsugel sold to KKR. | | | | | | |
| | | | | 12/2011: Kindler steps down, Read in. | | | | | | |
| | | | | 4/2012: Pfizer to divest Nutritionals to Nestle for $12bn. | | | | | | |
| | | | | 5/9/2012: 8-2 positive AdCom for tofacitinib. | | | | | | |
| | | | | 6/13: Divested Zoetis. | | | | | | |
| | | | | 2013: CAPITA Phase III Adult Prevnar results. | | | | | | |
| | | | | 7/28/22: Q222 results | | | | | | |